ArticleThe oncologist2023
Bone Metastases Detection in Patients with Breast Cancer: Does Bone Scintigraphy Add Information to PET/CT?
Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06205901 (A Prospective Comparison Study Between 18F-FDG PET/CT and Whole-Body Diffusion Weighted MRI in the Detection of Distant Malignancies in Patients With Various Cancers), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Comparison Study Between 18F-FDG PET/CT and Whole-Body Diffusion Weighted MRI in the Detection of Distant Malignancies in Patients With Various Cancers
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Diagnostic accuracy of imaging modalities for detection of spinal metastases: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [Diagnostics (Basel, Switzerland) · 2026Article
- The Impact of Staging Investigations in HER2-Low, Low-Risk Patients.Breast care (Basel, Switzerland) · 2026Article
- Age-Stratified Imaging Selection in Langerhans Cell Histiocytosis: Towards a Clinical Decision Framework.Journal of clinical medicine · 2026Article
- [18F]FDG PET/CT Radiomics in Untreated Breast Carcinoma: A Review of the Current State and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- A Deep Learning Model for Comprehensive Automated Bone Lesion Detection and Classification on Staging Computed Tomography Scans.Academic radiology · 2025Article
- Bone scan images dataset for study of bone metastases in adult breast cancer patients at IICS-UNA, Paraguay.Data in brief · 2025Article
- Can Ki-67 serve as a suitable marker to indicate the necessity of staging diagnostics in cases of low-risk breast cancer?Archives of gynecology and obstetrics · 2025Article
- Extensive thoracic vertebral and chest wall metastases as the initial presentation of breast cancer: a case report and literature review.Frontiers in oncology · 2025Review
- Artificial Intelligence and Radiomics Applied to Prostate Cancer Bone Metastasis Imaging: A Review.iRadiology · 2024Article
- 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the localization of the lesions in the osteogenic region of breast cancer bone metastases after therapy.Quantitative imaging in medicine and surgery · 2024Article
- Prospective comparison ofFrontiers in oncology · 2024Article
- Comparison of the diagnostic value of 18F-NaF PET/CT andTranslational cancer research · 2023Review
- Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary Management.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPositron emission tomography/computed tomography (PET/CT) has become in recent years a tool for breast cancer (BC) staging. However, its accuracy to detect bone metastases is classically considered inferior to bone scintigraphy (BS). The purpose of this work is to compare the effectiveness of bone metastases detection between PET/CT and BS. MATERIALS AND
methodsProspective study of 410 female patients treated in a Comprehensive Cancer Center between 2014 and 2020 that performed PET/CT and BS for staging purposes. The image analysis was performed by 2 senior nuclear medicine physicians. The comparison was performed based on accuracy, sensitivity, and specificity on a patient and anatomical region level and was assessed using McNemar's Test. An average ROC was calculated for the anatomical region analysis.
resultsPET/CT presented higher values of accuracy and sensitivity (98.0% and 93.83%), surpassing BS (95.61% and 81.48%) in detecting bone disease. There was a significant difference in favor of PET/CT (sensitivity 93.83% vs. 81.48%), however, there is no significant difference in eliminating false positives (specificity 99.09% vs. 99.09%). PET/CT presented the highest accuracy and sensitivity values for most of the bone segments, only surpassed by BS for the cranium. There was a significant difference in favor of PET/CT in the upper limb, spine, thorax (sternum) and lower limb (pelvis and sacrum), and in favor of BS in the cranium. The ROC showed that PET/CT has a higher sensitivity and consistency across the bone segments.
conclusionWith the correct imaging protocol, PET/CT does not require BS for patients with BC staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.